Drug profile · INN
omalizumab-igec
OMLYCLO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
omalizumab-igec (OMLYCLO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN omalizumab-igec
Brand OMLYCLO
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is omalizumab-igec?
omalizumab-igec (OMLYCLO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for omalizumab-igec?
OMLYCLO is a marketed brand name for omalizumab-igec. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omalizumab-igec?
omalizumab-igec has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.